leadf
logo-loader
RNS
viewErgomed PLC

Ergomed plc - Result of General Meeting

RNS Number : 4731C
Ergomed plc
19 October 2020
 

Ergomed Plc

Result of General Meeting

Guildford, UK - 19 October 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that at its General Meeting held today the special resolutions regarding the proposed Capital Reduction were passed with 100% shareholder approval (see table and notes below).

The Capital Reduction remains subject to the Court's approval and a directions hearing is scheduled for 28 October 2020.  If the Court is satisfied that the application should proceed, a second hearing will be held on 10 November 2020 to confirm the Capital Reduction.

A further announcement will be made following the Capital Reduction becoming effective.

 

Terms used but not defined in this announcement are as defined in the Company's announcement of 1 October 2020.

 

Details of the voting in respect of each resolution are shown in the table below:

 


For

Against

Withheld

Resolution

No. of Shares

%

No. of Shares

%

No. of Shares

1. To cancel the Company's Share Premium Account

41,339,888

100

2,000

0

1,414

2. To capitalise the Company's Merger Reserve by paying up B Shares

41,339,888

100

Nil

0

3,414

3. To cancel the B Shares

41,339,888

100

Nil

0

3,414

 

Notes:

 

1.     Votes "For" and "Against" are expressed as a percentage of votes received.

2.     A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3.     Percentages in relation to Resolution 1 are rounded.

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

[email protected]

Matthew Neal / Olivia Manser




 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMGCBDGCGBDGGC

Quick facts: Ergomed PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

4 min read